FATE THERAPEUTICS INC

Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting

03 May 2024 15:30:00 By Nasdaq GlobeNewswire

Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting

22 Apr 2024 15:30:00 By Nasdaq GlobeNewswire

Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference

03 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

02 Apr 2024 15:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement

19 Mar 2024 07:44:41 By Nasdaq GlobeNewswire

NetDania - New 12 months High: FATE THERAPEUTICS INC. - COMMON STOCK

07 Mar 2024 14:11:47 By NetDania Notify

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

05 Mar 2024 15:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics to Present at Upcoming March Investor Conferences

01 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: FATE THERAPEUTICS INC. - COMMON STOCK

27 Feb 2024 08:45:16 By NetDania Notify

Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

26 Feb 2024 15:01:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: FATE THERAPEUTICS INC. - COMMON STOCK

16 Feb 2024 09:00:35 By NetDania Notify

NetDania - New 12 months High: FATE THERAPEUTICS INC. - COMMON STOCK

15 Feb 2024 09:31:27 By NetDania Notify

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results

15 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

02 Feb 2024 15:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors

08 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

13 Dec 2023 16:00:00 By Nasdaq GlobeNewswire

Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

08 Nov 2023 15:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results

25 Oct 2023 07:00:01 By Nasdaq GlobeNewswire

Fate Therapeutics to Present at Upcoming September Investor Conferences

31 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates

08 Aug 2023 15:01:00 By Nasdaq GlobeNewswire